Core Insights - Regenerative Medical Technologies Group, Inc. has launched its CELLGENIC Peptide Pen product line, enhancing its position in the regenerative medicine market [1] - The introduction of this product line aims to simplify and modernize peptide therapy, aligning with trends in longevity medicine [1] - The new product line is expected to generate additional revenue through the company's established physician distribution network across over 30 countries [1] Company Overview - Regenerative Medical Technologies Group, Inc. is recognized as a global leader in regenerative medicine solutions [1] - The company is actively expanding its product offerings to meet the growing demand for innovative medical therapies [1] Market Impact - The launch of the CELLGENIC Peptide Pen is positioned to create new revenue streams, indicating a strategic move to capitalize on the expanding market for peptide therapies [1] - The product line's introduction during the ISSCA Global Summit highlights the company's commitment to innovation and leadership in the field [1]

Core Insights - AecorBio Inc. has completed a $1.5 million equity financing round, valuing the company at $30 million, to advance its lead peptide candidate FT-002a for advanced prostate cancer [1] - FT-002a is a first-in-class peptide co-therapeutic that targets tumor iron metabolism, addressing a significant market opportunity in resistant prostate cancer, estimated at over $2.5 billion annually [2] - Preclinical data shows FT-002a can significantly reduce tumor volume, achieving an 80% reduction when combined with standard care and up to 97% in hormone-sensitive cases [3] - AecorBio is developing a multi-asset pipeline with additional preclinical programs in hormone-dependent oncology and immunology, supported by a robust intellectual property portfolio [4] - The CEO of AecorBio expressed strong investor confidence and highlighted the potential of FT-002a as a transformative therapy for treatment-resistant prostate cancer [5] Company Overview - AecorBio Inc. focuses on developing novel bioactive peptides for therapeutic applications in oncology, inflammatory, and autoimmune diseases, with FT-002a as the lead candidate [6] - The company is leveraging its proprietary peptide discovery platform to advance multiple drug candidates, supported by strong intellectual property and global academic collaborations [6] - Hofseth BioCare ASA retains approximately 67.5% ownership of AecorBio after the financing round, which will result in a NOK 8 million gain in financial income for Hofseth in Q3 2025 [5]